RxDoctor Payments Data

Jonathan Parkhurst, MD

Internal Medicine · Middlebury, CTNPI 1164628889

Payments from drug & device makers

$10,548in general payments, 2019–2025

Across 599 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • GSK$898
  • Amarin Pharma, Inc.$718
  • Pfizer$703
  • Lilly USA, LLC$619
  • plus $5K from 53 others

What the payments were for

  • Speaking & faculty fees$120%
  • Food & beverage$10,40199%
  • Education$1351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk80$1,301
AbbVie(2 entities)67$1,101
GSK49$898
Amarin Pharma, Inc.43$718
Pfizer45$703
Lilly USA, LLC33$619
Boehringer Ingelheim28$514
AstraZeneca29$483
Bayer19$468
Merck25$344
Amgen17$338
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$261
Takeda Pharmaceuticals U.S.A., Inc.16$257
Novartis14$241
Astellas Pharma US Inc12$228
Abbott11$224
Lundbeck LLC9$204
Johnson & Johnson12$195
Otsuka America Pharmaceutical, Inc.6$111
Phathom Pharmaceuticals, Inc.5$85
Idorsia Pharmaceuticals US Inc4$78
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$76
Neurocrine Biosciences, Inc.4$74
Scilex Pharmaceuticals Inc.1$64
Xeris Pharmaceuticals, Inc.3$53
Ultragenyx Pharmaceutical Inc.3$48
Genentech USA, Inc.3$45
Ardelyx, Inc.2$42
E.r. Squibb & Sons, L.L.C.2$41
UCB, Inc.1$41
Endo Pharmaceuticals Inc.2$40
Sanofi-aventis U.S. LLC2$37
Teva Pharmaceuticals USA, Inc.2$35
Sunovion Pharmaceuticals Inc.3$35
Sanofi Pasteur Inc.2$33
Exact Sciences2$32
Irhythm Technologies, Inc.1$32
Strongbridge US Inc.2$31
Therapeuticsmd, Inc.2$31
Sumitomo Pharma America, Inc.1$28
Avanir Pharmaceuticals, Inc.2$27
Corcept Therapeutics1$26
MDD US Operations, LLC1$25
Eisai Inc.1$24
Nestle Healthcare Nutrition Inc.1$23
Axsome Therapeutics, Inc.1$22
Paratek Pharmaceuticals, Inc.1$22
Biohaven Pharmaceutical Holding Company Ltd.1$21
Regeneron Healthcare Solutions, Inc.1$20
Phadia US Inc.1$20
Radius Health, Inc.1$19
Intra-sana Laboratories1$17
Medtronic1$14
Arbor Pharmaceuticals, Inc.1$14
Ironwood Pharmaceuticals, Inc1$13
Alfasigma USA, Inc.1$13
Qiagen, LLC1$12
Kowa Pharmaceuticals America, Inc.1$12
Acorda Therapeutics, Inc1$12

How this compares

$10,548 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$72,133
Medicare patients
232
Services billed
971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$110,472
JardianceEmpagliflozin73$102,023
FarxigaDapagliflozin Propanediol60$68,410
EliquisApixaban75$64,321
JanuviaSitagliptin Phosphate41$54,492
XifaxanRifaximin13$39,360
LinzessLinaclotide38$29,987
KerendiaFinerenone15$25,173
TrulicityDulaglutide22$23,345
MounjaroTirzepatide23$22,735
XareltoRivaroxaban18$22,325
MyrbetriqMirabegron14$18,740
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,180
RybelsusSemaglutide12$14,610
VascepaIcosapent Ethyl43$14,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,301$125,08296 claims
Boehringer IngelheimJardiance$514$102,02373 claims
MerckJanuvia, Janumet Xr, Janumet$344$77,47571 claims
AstraZenecaFarxiga$483$68,41060 claims
PfizerEliquis$703$64,32175 claims
Lilly USA, LLCTrulicity, Mounjaro$619$46,08045 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$261$39,36013 claims
AbbVieLinzess, Synthroid$1,101$32,70566 claims
GSKTrelegy Ellipta, Breo Ellipta$898$32,21059 claims
BayerKerendia$468$25,17315 claims
Johnson & JohnsonXarelto$195$22,32518 claims
Astellas Pharma US IncMyrbetriq$228$18,74014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Middlebury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →